Drug Profile
MK 4830
Alternative Names: MK-4830Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Agenus
- Developer Merck Sharp & Dohme; Presage Biosciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; LILRB2 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ovarian cancer
- Discontinued Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours
Most Recent Events
- 20 Mar 2024 Discontinued - Phase-0 for Solid tumours (Combination therapy) in USA (Intratumoural)
- 20 Mar 2024 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada, Israel, USA (IV)
- 20 Mar 2024 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA, Israel, Canada (IV)